Cullinan Therapeutics Inc (CGEM)

Mar 30, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Swiss National Bank - Defense World

Mar 30, 2025

Mar 26, 2025

Charles Schwab Investment Management Inc. Has $5.25 Million Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 26, 2025

Mar 24, 2025

20,273 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Purchased by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 24, 2025

Mar 16, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.1% – Time to Sell? - Defense World

Mar 16, 2025

Mar 12, 2025

EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR

Mar 12, 2025

Mar 09, 2025

Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World

Mar 09, 2025

Mar 08, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 08, 2025

Mar 07, 2025

Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating - TipRanks

Mar 07, 2025

Mar 07, 2025

Rhumbline Advisers Raises Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 07, 2025

Mar 06, 2025

New York State Common Retirement Fund Buys 3,200 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Mar 06, 2025

Mar 06, 2025

Cullinan Therapeutics (CGEM) to Release Quarterly Earnings on Thursday - Defense World

Mar 06, 2025

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Given "Buy" Rating at HC Wainwright - MarketBeat

Mar 04, 2025

Mar 04, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Announces Earnings Results - MarketBeat

Mar 04, 2025

Mar 03, 2025

Q1 Earnings Estimate for CGEM Issued By William Blair - Defense World

Mar 03, 2025

Mar 03, 2025

Cullinan Therapeutics’ (CGEM) “Buy” Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025

Mar 01, 2025

Cullinan Therapeutics Inc (CGEM) Reports Q4 2024 Net Loss of $47 - GuruFocus.com

Mar 01, 2025

Feb 28, 2025

Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews

Feb 28, 2025

Feb 28, 2025

Cullinan Therapeutics: Q4 Earnings Snapshot - The Pioneer

Feb 28, 2025

Feb 28, 2025

Cullinan Therapeutics’ chief medical officer sells $41,754 in stock - Investing.com India

Feb 28, 2025

Feb 28, 2025

Cullinan Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Feb 28, 2025

Feb 27, 2025

Cullinan Therapeutics’ chief medical officer sells $41,754 in stock By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics CEO sells $106,872 in stock By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics CEO sells $106,872 in stock - Investing.com India

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics' chief medical officer sells $41,754 in stock - Investing.com

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics Reports Phase 1 Study Updates and Financial Results for Q4 2024 - Nasdaq

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire Inc.

Feb 27, 2025

Feb 26, 2025

Financial Review: Cullinan Therapeutics (NASDAQ:CGEM) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World

Feb 26, 2025

Feb 24, 2025

Cullinan Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 24, 2025

Feb 24, 2025

Exclusive Access: Cullinan Therapeutics Leadership Reveals Strategy at Elite Healthcare Forums - StockTitan

Feb 24, 2025

Feb 20, 2025

Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM) - SETE News

Feb 20, 2025

Feb 16, 2025

CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com

Feb 16, 2025

Feb 16, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month LowHere's Why - MarketBeat

Feb 16, 2025

Feb 14, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by Analysts - MarketBeat

Feb 14, 2025

Feb 14, 2025

FY2024 Earnings Estimate for CGEM Issued By Leerink Partnrs - MarketBeat

Feb 14, 2025

Feb 11, 2025

What is Leerink Partnrs’ Forecast for CGEM FY2024 Earnings? - Defense World

Feb 11, 2025

Feb 11, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of “Buy” by Brokerages - Defense World

Feb 11, 2025

Feb 10, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Feb 10, 2025

Feb 08, 2025

What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings? - Defense World

Feb 08, 2025

Feb 07, 2025

Ratio Revelations: Cullinan Therapeutics Inc (CGEM)’s Financial Metrics in the Spotlight - The Dwinnex

Feb 07, 2025

Feb 07, 2025

CGEM Stock Sees Decline of Approximately -5.74% in Last Five Days - Knox Daily

Feb 07, 2025

Feb 07, 2025

Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach - Fierce Biotech

Feb 07, 2025

Feb 06, 2025

SG Americas Securities LLC Has $283,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Feb 06, 2025

Feb 06, 2025

HC Wainwright Has Bearish Outlook for CGEM FY2025 Earnings - MarketBeat

Feb 06, 2025

Feb 03, 2025

Equities Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat

Feb 03, 2025

Feb 03, 2025

HC Wainwright Brokers Decrease Earnings Estimates for CGEM - Defense World

Feb 03, 2025